KRAS, KRAS proto-oncogene, GTPase, 3845

N. diseases: 1213; N. variants: 54
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0024121
Disease: Lung Neoplasms
Lung Neoplasms
0.600 Biomarker group BEFREE Based on published studies showing that oncogenic RAS promotes angiogenesis by upregulating the proangiogenic NF-κB target genes IL-8 and VEGF, that NF-κB activation by KRAS requires the IKKβ kinase, and that targeting IKKβ reduces KRAS-induced lung tumor growth in vivo, but has limited effects on cell growth in vitro, we hypothesized that IKKβ targeting would reduce lung tumor growth by inhibiting KRAS-induced angiogenesis. 30885340 2019
CUI: C0024121
Disease: Lung Neoplasms
Lung Neoplasms
0.600 Biomarker group BEFREE Genetic mutations in ALK, MET, ROS1, EGFR, and KRAS were chosen a priori for study based on availability by standard SNaPshot Lung Tumor Genotyping Analysis. 29652780 2018
CUI: C0024121
Disease: Lung Neoplasms
Lung Neoplasms
0.600 GeneticVariation group BEFREE RANKL blocking agents impair the growth of primary lung tumors in several mouse models of lung adenocarcinoma and suggest that patients with KRAS-mutant lung tumors will benefit from such treatments. 29223537 2018
CUI: C0024121
Disease: Lung Neoplasms
Lung Neoplasms
0.600 Biomarker group BEFREE RASSF1A deficiency profoundly enhanced the development of K-RAS-driven lung tumors <i>in vivo</i> Analysis of these tumors showed loss of RASSF1A-uncoupled RAS from the proapoptotic Hippo pathway as expected. 29735543 2018
CUI: C0024121
Disease: Lung Neoplasms
Lung Neoplasms
0.600 Biomarker group BEFREE Here, for the first time, we document that deltarasin produces both apoptosis and autophagy in KRAS-dependent lung cancer cells in vitro and inhibits lung tumor growth in vivo. 29440631 2018
CUI: C0024121
Disease: Lung Neoplasms
Lung Neoplasms
0.600 Biomarker group BEFREE We show that initiation and progression of KRAS-driven lung tumors require input from ERBB family receptor tyrosine kinases (RTKs): Multiple ERBB RTKs are expressed and active from the earliest stages of KRAS-driven lung tumor development, and treatment with a multi-ERBB inhibitor suppresses formation of KRAS<sup>G12D</sup>-driven lung tumors. 29925636 2018
CUI: C0024121
Disease: Lung Neoplasms
Lung Neoplasms
0.600 GeneticVariation group BEFREE Furthermore, our findings indicate that the well‑differentiated type of KRAS-mutant lung tumors depends, at least in part, on TTF‑1 for growth. 29658609 2018
CUI: C0024121
Disease: Lung Neoplasms
Lung Neoplasms
0.600 GeneticVariation group BEFREE We find no evidence of heterogeneity that may compromise KRAS G12C targeted therapy within sequenced lung tumors or passaged xenografts. 29453361 2018
CUI: C0024121
Disease: Lung Neoplasms
Lung Neoplasms
0.600 GeneticVariation group BEFREE These results suggest that targeting EGFR ligands may benefit patients who carry EGFR-mutant lung tumors but will not benefit patients with KRAS-mutant lung tumors. 29662194 2018
CUI: C0024121
Disease: Lung Neoplasms
Lung Neoplasms
0.600 Biomarker group CTD_human Caveolin-1 promotes the tumor suppressor properties of oncogene-induced cellular senescence. 29247004 2018
CUI: C0024121
Disease: Lung Neoplasms
Lung Neoplasms
0.600 Biomarker group BEFREE Combined downstream RAL-TBK1 and MEK inhibition induces only transient lung tumor shrinkage in KRAS-driven genetically engineered mouse models (GEMMs). 30205046 2018
CUI: C0024121
Disease: Lung Neoplasms
Lung Neoplasms
0.600 Biomarker group BEFREE Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours. 28414306 2017
CUI: C0024121
Disease: Lung Neoplasms
Lung Neoplasms
0.600 Biomarker group BEFREE Moreover, inactivating BRAF mutations have also been identified in a subset of KRAS-driven human lung tumours. 28783725 2017
CUI: C0024121
Disease: Lung Neoplasms
Lung Neoplasms
0.600 GeneticVariation group BEFREE They consisted primarily of G to A transition and G to T transversion in both the KRAS (41/56 or 73.2%) and TP53 (24/34 or 70.6%) genes, consistent with mutations found in lung tumors of smoking lung cancer patients. 27182622 2017
CUI: C0024121
Disease: Lung Neoplasms
Lung Neoplasms
0.600 Biomarker group BEFREE Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours. 28846116 2017
CUI: C0024121
Disease: Lung Neoplasms
Lung Neoplasms
0.600 Biomarker group BEFREE Also, in Hdac7 <sup>+/-</sup>/K-Ras mice, cell proliferation was significantly inhibited and apoptosis in lung tumors was greatly enhanced. 29126425 2017
CUI: C0024121
Disease: Lung Neoplasms
Lung Neoplasms
0.600 GeneticVariation group BEFREE Importantly, induction of FOXA3 or SPDEF along with mutant KRAS in lung epithelium was sufficient to develop benign or malignant mucinous lung tumors, respectively, in transgenic mice. 28255028 2017
CUI: C0024121
Disease: Lung Neoplasms
Lung Neoplasms
0.600 Biomarker group BEFREE By the nanoimmunoassay (NIA), KRAS is found to activate the protein ERK2, whereas ERK1 activation is found in non-KRAS-associated human lung tumors. 28400509 2017
CUI: C0024121
Disease: Lung Neoplasms
Lung Neoplasms
0.600 Biomarker group BEFREE When administered as a single agent or in combination with the standard-of-care drug carboplatin, ND-646 markedly suppressed lung tumor growth in the Kras;Trp53<sup>-/-</sup> (also known as KRAS p53) and Kras;Stk11<sup>-/-</sup> (also known as KRAS Lkb1) mouse models of NSCLC. 27643638 2016
CUI: C0024121
Disease: Lung Neoplasms
Lung Neoplasms
0.600 AlteredExpression group BEFREE Altogether our results illustrate the architecture of germline control of gene expression in mouse lung cancer: they highlight the importance of Pas1 as a tumor-modifier locus, attribute to it a novel role as a major regulator of transcription in lung tumor nodules and strengthen the candidacy of the Kras gene as the effector of this locus. 26966001 2016
CUI: C0024121
Disease: Lung Neoplasms
Lung Neoplasms
0.600 Biomarker group BEFREE Synchronous lung cancers from 60 patients (42 with adenocarcinoma and 18 with squamous cell carcinoma), clinically considered to represent intrapulmonary metastases, were histologically subtyped according to the 2015 World Health Organization classification of lung tumors and subjected to genotypic analysis (KRAS, EGFR, BRAF, PIK3CA, ALK, MET and ROS1 in adenocarcinoma and PIK3CA and p16 in squamous cell carcinoma). 27080983 2016
CUI: C0024121
Disease: Lung Neoplasms
Lung Neoplasms
0.600 GeneticVariation group BEFREE Coactivation of BRAF(V600E) and KRAS(G12D) markedly reduced lung tumor numbers and overall tumor burden compared with activation of BRAF(V600E) alone. 26028035 2016
CUI: C0024121
Disease: Lung Neoplasms
Lung Neoplasms
0.600 GeneticVariation group BEFREE Elderly male smokers with right lung tumors are viable candidates for KRAS mutation screening. 26739511 2016
CUI: C0024121
Disease: Lung Neoplasms
Lung Neoplasms
0.600 Biomarker group BEFREE Compared with lung tumors from K-Ras mice, the levels of prostaglandin E2 (PGE2) were significantly lower, whereas levels of the PGE2 metabolite 13,14-dihydro-15-keto-PGE2 were significantly higher, in lung tumors from K-ras/COX-2(-/-) mice. 26452035 2015
CUI: C0024121
Disease: Lung Neoplasms
Lung Neoplasms
0.600 GeneticVariation group BEFREE As expected, KRAS mutations were the most common alteration found (63% of cases); however, the distribution of nucleotide position alterations was more similar to that observed in gastrointestinal tumors than other lung tumors. 26200269 2015